Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
An FDA advisory committee has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine for use in expectant mothers, potentially opening up a niche for the shot, where it won’t have to face ...
Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance ... a rare side effect seen with both GSK and Pfizer’s products. There’s still one ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Sales of both GSK’s and Pfizer’s vaccines for respiratory syncytial virus dropped significantly ... The Food and Drug Administration cleared GSK’s shot for adults aged 50 to 59 years who ...
US health chiefs issued a warning about RSV jabs, which were only launched in Britain last year.In the UK, the condition is already noted as a potential complication in patient information.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback